SELF-INTRODUCTION：

Dr. Liu finished her postdoc training in the Department of Biochemistry, School of Medicine, Southern University of Science and Technology from 2020 to 2022 and won the honorary title of Shenzhen Overseas High-level Talents (Category C) in 2021.

Dr. Liu received her doctoral degree in Medicine at Guangzhou University of Chinese Medicine in 2020. As a visiting scholar from 2019-2020 at Harvard Medical School, Dr. Liu focused on endothelial progenitor cells (EPC) for the treatment of acute kidney injury. The relevant research results were published in the Journal of The American Society of Nephrology, American Journal of Pathology, Clinical Pharmacokinetics, Nephrology Dialysis Transplantation, Fronierst in Immunology, Frontiers in Genetics.

Dr. Liu presided over 2 projects of the General Program of National Natural Science Foundation of China (82204882) and Medical Scientific Research Foundation of Guangdong Province (A2023153), and as a key member participated in the National Key R&D Program of China (SQ2023YFC2400090), national-level projects (82173391, 82171416) and ministerial level projects (A2021032, 2021KTSCX108) and Shenzhen municipal projects (JCYJ20210324104204013).

EDUCATION:

• September 2017-June 2020

  Ph.D. in Renal Disease Laboratory, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, China

• March 2019-March 2020

  Visiting student in the Department of Nephrology, Brigham and Women’s Hospital, Harvard Medical School, US

• September 2014-June 2017

  Master of Medical degree in Department of Hemodialysis, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, China

• September 2009-June 2014

  Bachelor of Medical degree in Integrated Chinese and Western Medicine, ShanXi University of Chinese Medicine, China

WOKRING EXPERIENCE:

• October 2020-November 2022 Postdoctoral Fellow

  Advisor: Prof. Xin Hong Department of Biochemistry, Southern University of Science and Technology, China

• December 2022 to September 2023 Senior Research Scholar

  Advisor: Prof. Xin Hong Department of Biochemistry, Southern University of Science and Technology, China

• November 2023 to now Research Assistant Professor

  Department of Biochemistry, Southern University of Science and Technology, China

HONORS AND AWARDS:

• In March 2021, recognized as Overseas High-Caliber Personnel (Level C, Peacock Plan) in Shenzhen, Guangdong, China.

• In 2020, won the title of “Outstanding graduate student” in Guangzhou University of Chinese Medicine.

• Won the 2018 Guangzhou University of Chinese Medicine “International Exchange Program” for a one-year visit to Harvard Medical School in the United States.

• From 2014 to 2019, got a major scholarship from Guangzhou University of Chinese Medicine per year.

RESEARCH:

Identification of novel therapeutic strategies against metastasis using patient-derived model systems, dedicated to studying the fundamental biology of human cancer, and translating these breakthroughs from bench to bedside.

PUBLICATIONS：

First or co-first author papers

1. Jialing Liu*; Yi Li*; Lingna Lyu; Liang Xiao; Aliza Anwar Memon; Xin Yu; Arvin Halim; Shivani Patel; Abdikheyre Osman; Wenqing Yin; Jie Jiang; Said Naini; Kenneth Lim; Aifeng Zhang; Jonathan Williams; Ruth Koester; Kevin Zeng Qi; Quynh-Anh Fucci; Lai Ding; Steven Chang; Ankit Patel; Yutaro Mori; Advika Chaudhari; Aaron Bao; Jia Liu; Tzongshi Lu; Andrew Siedlecki; Integrin alpha-5 is regulated by miR- 218-5p in endothelial progenitor cells, Journal of The American Society of  Nephrology, 2022, 33(3): 565-582. (*Equal contributions)

2. Jialing Liu*; Yanmei Zhang*; Hongqin Sheng*; Chunling Liang; Huazhen Liu;Jose Alberto Moran Guerrero; Zhaoyu Lu; Wei Mao; Zhenhua Dai†; Xusheng Liu†; Lei Zhang†; Hyperoside Suppresses Renal Inflammation by Regulating Macrophage Polarization in Mice with Type 2 Diabetes Mellitus, Frontiers in  Immunology, 2021.12. (*Equal contributions; † co-corresponding authors)

3. Wang, Xiaojie*; Liu, Jialing*; Yin, Wenqing; Abdi, Farhiya; Pang, Paul D; Fucci, Quynh-Anh;Abbott, Molly; Chang, Steven L; Steele, Graeme; Patel, Ankit; Mori, Yutaro; Zhang, Aifeng; Zhu, Shikai; Lu, Tzong-Shi; Kibel, Adam S; Wang, Bin; Lim, Kenneth; Siedlecki, Andrew M; miR-218 Expressed in Endothelial Progenitor Cells Contributes to the Development and Repair of the Kidney Microvasculature, The American Journal of Pathology, 2020, 190(3): 642-659. (*Equal contributions)

4. Jialing Liu; Aliza Anwar Memon; Lingna Lyu; Andrew Siedlecki; Comment on “Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab”, Clinical  Pharmacokinetics, 2020, 59(12): 1641-1643.

5. Jialing Liu; Jingru Lian; Yafei Chen; Xin Zhao; ChangZheng Du; Yang Xu; Hailiang Hu; Hai Rao; Xin Hong ; Circulating Tumor Cells (CTCs): A Unique Model of Cancer Metastases and Non-invasive Biomarkers of Therapeutic Response. Frontiers in Genetics, 2021, 12.

International conferences

1. Poster presentation. Jialing Liu*; Chunling Liang; Xusheng Liu; Yueming Luo; Zhaoyu Lu; Lei Zhang: The role of macrophage phenotypes in type 2 diabetic nephropathy progression. 2019 ERA-EDTA Congress. Nephrology Dialysis Transplantation.

2. Poster presentation. Jialing Liu*, Yueming Luo, Zhang Lei, Heng Weng, Xusheng Liu. Prevalence in firstly accepted hemodialysis patients and insomnia symptoms between DKD and other primary causes in Guangdong. 2017 Chinese Medical Association Nephrology Annual Meeting (CSN).

3. Poster presentation. Tzongshi Lu, Kenneth Lim, Michelle Song, Jialing Liu, Andrew Siedlecki, Ravi Thadhani, Sahir Kalim. Carbamylated homocitrulline is associated with left ventricular hypertrophy in CKD: Results from The CAIN Study. ASN Congress in 2019.

4. Poster presentation. Xusheng Liu, Yueming Luo, Yuqun Zeng, Jialing Liu, Heng Weng. Visualization of symptoms ontology in maintenance hemodialysis patients. ERA-EDTA Congress in 2018. Nephrology Dialysis Transplantation.

Grants as the Principle Investigator

1. General Program of National Natural Science Foundation of China (Grant No. 82204882). Project title “Molecular dialogue mechanism between circulating tumor cells (CTC) and vascular endothelial progenitor cells (VEPC) and the therapeutic strategy of traditional Chinese medicine monomers”. (PI, 300,000 RMB, 2023-01-01 to 2025-12-31).

2. Medical Scientific Research Foundation of Guangdong Province (Grant No. A2023153). Project title “Vascular endothelial progenitor cell (EPC)-derived exosomal miRNAs regulate long-range breast cancer invasion Mechanism research”. (PI, 10,000 RMB, 2023-07-01 to 2025-06-30).

Grants as a Key Participant

1. General Program of National Natural Science Foundation of China (Grant No. 82173391). Project title “Use of Circulating Tumor Cell-derived Animal Models (CDX) to Investigate Molecular Mechanisms of Melanoma Metastasis”. (Participant, 547,000 RMB,2022-01-01 to 2025-12-31).

2. General Program of National Natural Science Foundation of China (Grant No. 82171416), Project title “The study of selective susceptibility to neurodegenerative diseases by using genome-wide CRISPRi/a”. (Participant, 550,000RMB,2022-01- 01 to 2025-12-31).

3. Shenzhen Municipal Foundation, (Grant No. JCYJ20210324104204013).Project title “Use of Circulating Tumor Cell-derived Models to Investigate Hippo Pathway-mediated Drug Resistance Mechanisms in Metastatic Melanoma”. (Participant, 600,000 RMB, 2021-04 to 2024-03）.

4. Guangdong Province Medical Science and Technology Research Fundation, (Grant No. A2021032）, Project title “Mechanistic Investigation of Inducible      Ferroptotic Cell Death and Drug Resistance in Circulating Melanoma Cells. (Participant, 10,000 RMB, 2021-07 to 2023-06）.

5. Featured Innovation Projects of General Colleges and Universities in Guangdong Province. (Grant No. 2021KTSCX108 ）, Project title “Investigation of Breast Cancer Metastasis in Circulating Tumor Cell-derived Animal Models (CDX)”.(Participant, 80,000 RMB, 2021-09 to 2023-08).

6. Guangdong Provincial Basic and Applied Basic Research Fund - Natural Science Foundation of China (general project). Project title “The molecular mechanism and clinical translation research of c-JUN/FOS signaling pathway regulating the distant metastasis of circulating tumor cells (CTC).” （Participant, 100,000 RMB,2023-01-01 to 2025-12-31）.